GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Cash-to-Debt

PURE Bioscience (PURE Bioscience) Cash-to-Debt : 0.30 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PURE Bioscience's cash to debt ratio for the quarter that ended in Jan. 2024 was 0.30.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, PURE Bioscience couldn't pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for PURE Bioscience's Cash-to-Debt or its related term are showing as below:

PURE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3   Med: No Debt   Max: No Debt
Current: 0.3

During the past 13 years, PURE Bioscience's highest Cash to Debt Ratio was No Debt. The lowest was 0.30. And the median was No Debt.

PURE's Cash-to-Debt is ranked worse than
61.31% of 1853 companies
in the Consumer Packaged Goods industry
Industry Median: 0.53 vs PURE: 0.30

PURE Bioscience Cash-to-Debt Historical Data

The historical data trend for PURE Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PURE Bioscience Cash-to-Debt Chart

PURE Bioscience Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt 10.00 No Debt 1.07

PURE Bioscience Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt 1.07 0.79 0.30

Competitive Comparison of PURE Bioscience's Cash-to-Debt

For the Household & Personal Products subindustry, PURE Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Cash-to-Debt falls into.



PURE Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PURE Bioscience's Cash to Debt Ratio for the fiscal year that ended in Jul. 2023 is calculated as:

PURE Bioscience's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PURE Bioscience  (OTCPK:PURE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


PURE Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


PURE Bioscience (PURE Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.
Executives
Robert F Bartlett director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee director 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor director 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno director 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers officer: Chief Operating Officer 1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert director, officer: Chief Executive Officer 1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field director 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc 10 percent owner 325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott officer: Vice President, Finance 1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis director 1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno director 1725 GILLESPIE WAY, EL CAJON CA 92020